{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:19:42Z","timestamp":1758050382196,"version":"3.44.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"am","delay-in-days":405,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bulcan.2019.12.004","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T18:07:55Z","timestamp":1579630075000},"page":"48-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Traitement adjuvant des voies biliaires\u00a0: qui et comment\u00a0?"],"prefix":"10.1016","volume":"107","author":[{"given":"Julien","family":"Edeline","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9935","key":"10.1016\/j.bulcan.2019.12.004_bib0125","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0140-6736(13)61903-0","article-title":"Cholangiocarcinoma","volume":"383","author":"Razumilava","year":"2014","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.bulcan.2019.12.004_bib0130","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/SLA.0b013e318236c21d","article-title":"Influence of surgical margins on outcome in patients with intrahepatic cholangiocarcinoma: a multicenter study by the AFC-IHCC-2009\u00a0study group","volume":"254","author":"Farges","year":"2011","journal-title":"Annals of surgery"},{"issue":"5","key":"10.1016\/j.bulcan.2019.12.004_bib0135","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jso.24165","article-title":"The true prognosis of resected distal cholangiocarcinoma","volume":"113","author":"Courtin-Tanguy","year":"2016","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.12.004_bib0140","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/hpb.12296","article-title":"Tumour size over 3cm predicts poor short-term outcomes after major liver resection for hilar cholangiocarcinoma. By the HC-AFC-2009\u00a0group","volume":"17","author":"Regimbeau","year":"2015","journal-title":"HPB (Oxford)"},{"issue":"5","key":"10.1016\/j.bulcan.2019.12.004_bib0145","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"The Oncologist"},{"issue":"23","key":"10.1016\/j.bulcan.2019.12.004_bib0150","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.2011.35.6519","article-title":"Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment","volume":"29","author":"de Jong","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.bulcan.2019.12.004_bib0155","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surgery"},{"issue":"43","key":"10.1016\/j.bulcan.2019.12.004_bib0160","doi-asserted-by":"crossref","first-page":"12211","DOI":"10.3748\/wjg.v21.i43.12211","article-title":"Gallbladder carcinoma: Prognostic factors and therapeutic options","volume":"21","author":"Goetze","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"14","key":"10.1016\/j.bulcan.2019.12.004_bib0165","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.bulcan.2019.12.004_bib0170","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjc.6604628","article-title":"Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study","volume":"99","author":"Andr\u00e9","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2019.12.004_bib0175","volume":"3","author":"Lamarca","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2019.12.004_bib0180","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.bulcan.2019.12.004_bib0185","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1200\/JCO.2011.40.5381","article-title":"Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis","volume":"30","author":"Horgan","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2019.12.004_bib0190","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.12.004_bib0195","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.bulcan.2019.12.004_bib0200","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3\u00a0study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2019.12.004_bib0205","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S1470-2045(19)30022-1","article-title":"Adjuvant capecitabine in biliary tract cancer: a standard option?","volume":"20","author":"Malka","year":"2019","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.bulcan.2019.12.004_bib0210","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.2014.60.2219","article-title":"SWOG S0809: a phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma","volume":"33","author":"Ben-Josef","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.12.004_bib0215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2012.7352","article-title":"Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3\u00a0periampullary cancer randomized trial","volume":"308","author":"Neoptolemos","year":"2012","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bulcan.2019.12.004_bib0220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/1066896916664987","article-title":"Differential expression of beta-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2\u00a0in intestinal and pancreatobiliary-type ampullary carcinomas","volume":"25","author":"Perysinakis","year":"2017","journal-title":"Int J Surg Pathol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.12.004_bib0225","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation. Followed by liver transplantation, for perihilar cholangiocarcinoma at 12\u00a0US centers","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bulcan.2019.12.004_bib0230","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/bjs.10641","article-title":"Neoadjuvant chemotherapy for initially unresectable intrahepatic cholangiocarcinoma","volume":"105","author":"Le Roy","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.bulcan.2019.12.004_bib0235","article-title":"Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","author":"Edeline","year":"2019","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.bulcan.2019.12.004_bib0120","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.18.02178","article-title":"Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline","volume":"37","author":"Shroff","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511930431X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511930431X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:32:13Z","timestamp":1757791933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745511930431X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S000745511930431X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.12.004","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Traitement adjuvant des voies biliaires\u00a0: qui et comment\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}